Health Care & Life Sciences » Biotechnology | RegeneRX Biopharmaceuticals Inc.

RegeneRX Biopharmaceuticals Inc.

RegeneRX Biopharmaceuticals Inc.
Stock Exchange Other OTC
Market Cap
$22.34 M
Shares Outstanding
131.51 M
Public Float
63.65 M


15245 Shady Grove Road
Rockville Maryland 20850
United States
Employees -
Updated 07/08/2019
RegeneRx Biopharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4, for tissue and organ protection, repair, and regeneration. The firm evaluates the commercial development of peptide fragments and derivatives of Tß4 for potential cosmeceutical and other personal care uses. Its products include RGN-259, RGN-352, and RGN-137.


View All

Allan L. Goldstein
Chairman & Chief Scientific Officer
J. J. Finkelstein
President, Chief Executive Officer & Director